Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Amgen Inc.

(AMGN)

David Stone of Cowen & Co. reiterated a "strong buy" after ABTI's Betafectin results came under fire primarily because of the study design.

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE